The RS is meaningless at this juncture. It has ZERO impact on the science and it will not impact buyout price. The price per share will be higher but with fewer shares. Way too much emphasis is being placed on the RS. It's all about approval. Will it be approved. I think yes.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.